Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol

• Published in: Anticancer research Vol. 38; no. 10; pp. 5831 - 5835
• Main Authors: Kenyon, Julian, Liu, Wai, Dalgleish, Angus
• Format: Journal Article
• Language: English
• Published: Greece International Institute of Anticancer Research 01.10.2018
• Subjects: Aged; Anticancer properties; Antineoplastic Agents - therapeutic use; Antitumor activity; Breast cancer; Cachexia; Cancer; Cannabidiol - therapeutic use; Cannabinoids; Data processing; Female; Glioma; Humans; Male; Nausea; Neoplasms - drug therapy; Pain; Patients; Pharmaceutical Preparations - administration & dosage; Pharmaceuticals; Prognosis; Reduction; Side effects; Solid tumors; Tumors; ependymoma; breast cancer; cannabinoids; prostate cancer; Cancer
• ISSN: 0250-7005; 1791-7530
• DOI: 10.21873/anticanres.12924

Cannabinoids are widely used in the management of pain, nausea and cachexia in cancer patients. However, there has been no objective clinical evidence of any anticancer activity yet. The aim of this study was to assess the effects of pharmaceutical-grade synthetic cannabidiol on a range of cancer patients. We analysed the data routinely collected, as part of our treatment program, in 119 cancer patients over a four-year period. Clinical responses were seen in 92% of the 119 cases with solid tumours including a reduction in circulating tumour cells in many cases and in other cases, a reduction in tumour size, as shown by repeat scans. No side-effects of any kind were observed when using pharmaceutical grade synthetic cannabidiol. Pharmaceutical-grade synthetic cannabidiol is a candidate for treating breast cancer and glioma patients.